Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02960399 · ClinicalTrials.gov registry record · NA
Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older
A NA study, sponsored by University of South Florida.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT02960399 is a NA study that was terminated before completion, run by University of South Florida. The registered enrollment target is 2 participants.
The verdict
NCT02960399, a NA study, was terminated before completion, sponsored by University of South Florida.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
Recommendations concerning the administration of Zostavax® in patients with antibody deficiency are unclear. The investigators plan to assess the immunogenicity and safety of Zostavax® in patients with antibody deficiency as compared with healthy volunteers.
Interventions
- BIOLOGICAL Zostavax®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-12 |
| Est. Completion | 2017-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02960399
The ClinicalTrials.gov registry entry for NCT02960399 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zostavax® is the first listed.
NCT02960399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02960399 about?
NCT02960399 is a clinical study titled "Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older". Recommendations concerning the administration of Zostavax® in patients with antibody deficiency are unclear. The investigators plan to assess the immunogenicity and safety of Zostavax® in patients with antibody deficiency as compared with healthy volunteers.
What is the current status of trial NCT02960399?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2015-12. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02960399?
The interventions under investigation include: Zostavax® (BIOLOGICAL).
Who is sponsoring clinical trial NCT02960399?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.